Relmada Therapeutics addresses areas of high unmet needs in depression, CNS and ophthalmological disorders.
Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders.
Novel NMDA receptor antagonist in Phase 2 clinical testing for the treatment of depression, and preclinical development for Rett syndrome and other indications.
Extended release, abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed.
Novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications.
Topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia (PHN) and HIV-associated neuropathy.
Our efforts are guided by highly experienced drug development leadership and world-class scientific advisors that provide the expertise to efficiently advance product development.